Immunitybio Inc IBRX

Healthcare Biotechnology

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

NDAQ:IBRX - Post by User

Immunitybio Inc

Bullboard Posts

Post by Covey1000on Jun 03, 2020 11:57am

333 Views

Post# 31106871

doubled investment in 3 weeks

Id say NK has considerable upside yet. They are on the warp 14 list for covid 19 vaccine development, their serum base has already been tested safe in patients with compromised immunity in cancer trials. Their vaccine trials begin this month. Their proposed vaccine can be multipurposed as vaccine, booster and treatment. They have production availability to hit the required 100 million doses by Jan of 2021.

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects